Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 9427583, 10 pages
https://doi.org/10.1155/2017/9427583
Research Article

Pterostilbene 4′-β-Glucoside Protects against DSS-Induced Colitis via Induction of Tristetraprolin

1Department of Biological Sciences, University of Ulsan, Ulsan 680-749, Republic of Korea
2Department of Clinical Laboratory Science, Wonkwang Health Science University, Iksan 570-750, Republic of Korea
3Department of Life Science, Okayama University, Okayama 770-0005, Japan

Correspondence should be addressed to Hun Taeg Chung

Received 22 December 2016; Revised 27 March 2017; Accepted 11 April 2017; Published 18 May 2017

Academic Editor: Takuya Akiyama

Copyright © 2017 Yingqing Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Fiocchi, “Inflammatory bowel disease: etiology and pathogenesis,” Gastroenterology, vol. 115, no. 1, pp. 182–205, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Xavier and D. K. Podolsky, “Unravelling the pathogenesis of inflammatory bowel disease,” Nature, vol. 448, no. 7152, pp. 427–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. H. Farzaei, R. Rahimi, and M. Abdollahi, “The role of dietary polyphenols in the management of inflammatory bowel disease,” Current Pharmaceutical Biotechnology, vol. 16, no. 3, pp. 196–210, 2015. View at Google Scholar
  4. J. Yao, J. Y. Wang, L. Liu et al., “Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis,” Archives of Medical Research, vol. 41, no. 4, pp. 288–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Langcake and R. J. Pryce, “A new class of phytoalexins from grapevines,” Experientia, vol. 33, no. 33, pp. 151-152, 1977. View at Google Scholar
  6. S. Paul, A. M. Rimando, H. J. Lee, Y. Ji, B. S. Reddy, and N. Suh, “Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells,” Cancer Prevention Research (Philadelphia, Pa.), vol. 2, no. 7, pp. 650–657, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Mikstacka and E. Ignatowicz, “Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer,” Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskego, vol. 28, no. 168, pp. 496–500, 2010. View at Google Scholar
  8. Y. S. Chiou, M. L. Tsai, Y. J. Wang et al., “Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice,” Journal of Agricultural and Food Chemistry, vol. 58, no. 15, pp. 8833–8841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Baur, K. J. Pearson, N. L. Price et al., “Resveratrol improves health and survival of mice on a high-calorie diet,” Nature, vol. 444, no. 7117, pp. 337–342, 2006. View at Google Scholar
  10. D. McCormack and D. McFadden, “A review of pterostilbene antioxidant activity and disease modification,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 575482, p. 15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. P. S. Son, S. A. Park, H. K. Na, D. M. Jue, S. Kim, and Y. J. Surh, “Piceatannol, a catechol-type polyphenol, inhibits phorbol ester-induced NF-{kappa}B activation and cyclooxygenase-2 expression in human breast epithelial cells: cysteine 179 of IKK{beta} as a potential target,” Carcinogenesis, vol. 31, no. 8, pp. 1442–1449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Sato, N. Shimizu, Y. Shimizu et al., “Synthesis of glycosides of resveratrol, pterostilbene, and piceatannol, and their anti-oxidant, anti-allergic, and neuroprotective activities,” Bioscience, Biotechnology, and Biochemistry, vol. 78, no. 7, pp. 1123–1128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Perez-Torres, R. Cortes, M. Tolnay, A. Probst, J. M. Palacios, and G. Mengod, “Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer’s disease brains examined by in situ hybridization,” Experimental Neurology, vol. 182, no. 2, pp. 322–334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. P. R. Heckman, C. Wouters, and J. Prickaerts, “Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer’s disease: a translational overview,” Current Pharmaceutical Design, vol. 21, no. 3, pp. 317–331, 2015. View at Google Scholar
  15. K. Ogawa, F. Chen, Y. J. Kim, and Y. Chen, “Transcriptional regulation of tristetraprolin by transforming growth factor-beta in human T cells,” The Journal of Biological Chemistry, vol. 278, no. 32, pp. 30373–30381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Yamada, S. Marshall, R. D. Specian, and M. B. Grisham, “A comparative analysis of two models of colitis in rats,” Gastroenterology, vol. 102, no. 5, pp. 1524–1534, 1992. View at Publisher · View at Google Scholar
  17. Y. Yan, V. Kolachala, G. Dalmasso et al., “Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis,” PloS One, vol. 4, no. 6, article e6073, 2009. View at Google Scholar
  18. G. Stoecklin and P. Anderson, “Posttranscriptional mechanisms regulating the inflammatory response,” Advances in Immunology, vol. 89, pp. 1–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. B. Shyu and M. F. Wilkinson, “The double lives of shuttling mRNA binding proteins,” Cell, vol. 102, no. 2, pp. 135–138, 2000. View at Publisher · View at Google Scholar
  20. E. Carballo, W. S. Lai, and P. J. Blackshear, “Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin,” Science, vol. 281, no. 5379, pp. 1001–1005, 1998. View at Publisher · View at Google Scholar
  21. E. Carballo, W. S. Lai, and P. J. Blackshear, “Evidence that tristetraprolin is a physiological regulatorof granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability,” Blood, vol. 95, no. 6, pp. 1891–1899, 2000. View at Google Scholar
  22. G. Stoecklin, X. F. Ming, R. Looser, and C. Moroni, “Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway,” Molecular and Cellular Biology, vol. 20, no. 11, pp. 3753–3763, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Boutaud, D. A. Dixon, J. A. Oates, and H. Sawaoka, “Tristetraprolin binds to the COX-2 mRNA 3′ untranslated region in cancer cells,” Advances in Experimental Medicine and Biology, vol. 525, pp. 157–160, 2003. View at Google Scholar
  24. K. Phillips, N. Kedersha, L. Shen, P. J. Blackshear, and P. Anderson, “Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2011–2016, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Linker, A. Pautz, M. Fechir, T. Hubrich, J. Greeve, and H. Kleinert, “Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR,” Nucleic Acids Research, vol. 33, no. 15, pp. 4813–4827, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. L. Ogilvie, M. Abelson, H. H. Hau, I. Vlasova, P. J. Blackshear, and P. R. Bohjanen, “Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay,” Journal of Immunology (Baltimore, Md.:1950), vol. 174, no. 2, pp. 953–961, 2005. View at Google Scholar
  27. G. A. Taylor, E. Carballo, D. M. Lee et al., “A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency,” Immunity, vol. 4, no. 5, pp. 445–454, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Sauer, B. Schaljo, C. Vogl et al., “Interferons limit inflammatory responses by induction of tristetraprolin,” Blood, vol. 107, no. 12, pp. 4790–4797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Joe, M. J. Uddin, M. Zheng et al., “Tristetraprolin mediates anti-inflammatory effect of carbon monoxide against DSS-induced colitis,” PloS One, vol. 9, no. 2, article e88776, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. K. Kundu and Y. J. Surh, “Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives,” Cancer Letters, vol. 269, no. 2, pp. 243–261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. F. Lee, M. L. Liu, A. C. Cheng et al., “Pterostilbene inhibits dimethylnitrosamine-induced liver fibrosis in rats,” Food Chemistry, vol. 138, no. 2-3, pp. 802–807, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Li, R. Deng, X. Hua et al., “Blueberry component pterostilbene protects corneal epithelial cells from inflammation via anti-oxidative pathway,” Scientific Reports, vol. 14, no. 6, pp. 1–10, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Benlloch, E. Obrador, S. L. Valles et al., “Pterostilbene decreases the antioxidant defenses of aggressive cancer cells in vivo: a physiological glucocorticoids- and Nrf2-dependent mechanism,” Antioxidants & Redox Signaling, vol. 24, no. 17, pp. 974–990, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. M. K. Jeengar, S. Shrivastava, K. Nair et al., “Improvement of bioavailability and anti-inflammatory potential of curcumin in combination with emu oil,” Inflammation, vol. 37, no. 6, pp. 2139–2155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Garside, “Cytokines in experimental colitis,” Clinical and Experimental Immunology, vol. 118, no. 3, pp. 337–339, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Autschbach, T. Giese, N. Gassler et al., “Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn’s disease,” Virchows Archiv: An International Journal of Pathology, vol. 441, no. 5, pp. 500–513, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Rubio-Perez and J. M. Morillas-Ruiz, “A review: inflammatory process in Alzheimer’s disease, role of cytokines,” The Scientific World Journal, vol. 2012, Article ID 756357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. K. R. Mahtani, M. Brook, J. L. Dean, G. Sully, J. Saklatvala, and A. R. Clark, “Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability,” Molecular and Cellular Biology, vol. 21, no. 19, pp. 6461–6469, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. C. R. Tchen, M. Brook, J. Saklatvala, and A. R. Clark, “The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself,” The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32393–32400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. C. A. Chrestensen, M. J. Schroeder, J. Shabanowitz et al., “MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding,” The Journal of Biological Chemistry, vol. 279, no. 11, pp. 10176–10184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Stoecklin, T. Stubbs, N. Kedersha et al., “MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay,” The EMBO Journal, vol. 23, no. 6, pp. 1313–1324, 2004. View at Publisher · View at Google Scholar · View at Scopus